Abbott Laboratories (ABT) Long-Term Deferred Tax (2009 - 2026)

Abbott Laboratories (ABT) has 16 years of Long-Term Deferred Tax data on file, last reported at $18.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Deferred Tax rose 9.04% year-over-year to $18.4 billion; the trailing twelve-month figure through Mar 2026 stood at $18.4 billion (up 9.04% YoY), and the FY2025 full-year result was $18.4 billion, up 11.93% from the prior year.
• Long-Term Deferred Tax held at $18.4 billion in Q1 2026, from $18.4 billion in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $18.4 billion in Q4 2025 to a low of $5.4 billion in Q2 2022.
• A 5-year average of $10.4 billion and a median of $7.5 billion in 2024 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax jumped 131.91% in 2024 and increased 9.04% in 2026, its largest moves.
• Tracing ABT's Long-Term Deferred Tax over 5 years: stood at $6.0 billion in 2022, then climbed by 17.64% to $7.1 billion in 2023, then jumped by 131.91% to $16.5 billion in 2024, then advanced by 11.93% to $18.4 billion in 2025, then decreased by 0.35% to $18.4 billion in 2026.
• Business Quant data shows ABT's Long-Term Deferred Tax at $18.4 billion in Q1 2026, $18.4 billion in Q4 2025, and $17.3 billion in Q3 2025.